Merck Stock Dips 1.95% as EPS Forecast Falls 118%, P/E Premium Rises
Merck shares slid 1.95% to $121.41 as the anticipated quarter shows EPS forecast of -$0.41 (118.47% decline) and revenue forecast of $16.01B (+3.09%). Valuation sits at a premium forward P/E of 22.5 versus the 16.0 industry average, and a Zacks Rank #4 indicates a sell.
1. Stock Performance
Merck shares dipped 1.95% to close at $121.41, trailing the S&P 500’s 0.04% gain. Over the past month, shares have climbed 12.29%, outperforming the Medical sector’s 0.92% rise and the S&P 500’s 1.33% decline.
2. Earnings Forecast
The upcoming quarter is expected to report an EPS of -$0.41, a 118.47% drop year-over-year, on revenue of $16.01 billion, marking a 3.09% increase from the same quarter last year. For the full year, EPS is projected at $5.50 (down 38.75%) and revenue at $66.68 billion (up 2.57%).
3. Valuation and Analyst Sentiment
Shares trade at a forward P/E of 22.53, a premium to the industry average of 16.02, while the PEG ratio stands at 2.24 compared with the industry’s 2.33 average. The stock carries a Zacks Rank #4 (Sell), reflecting a 17.16% decline in consensus EPS estimates over the past month.
4. Industry Standing
Merck operates within the Large Cap Pharmaceuticals industry, which ranks 172nd out of over 250 industries, placing it in the bottom 30% of sectors by average analyst ratings. This ranking suggests weaker sector momentum relative to peers.